Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) RAHWAY, NJ, USA I June 13, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced h

Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA MUNICH, Germany I June 13, 2025 I Ethris GmbH , a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. Th

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA, USA I June 12, 2025 I Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previou

WellMedica’s new anti-aging program offers personalized care, including BHRT pellet therapy and menopause fatigue treatment in Northern Virginia. RESTON, VA, UNITED STATES, June 13, 2025 / EINPresswire.com / -- With more adults seeking personalized and preventive approaches to aging, medical practices are expanding their focus beyond cosmetic care to address the physiological changes that occur over time. In Northern Virginia, WellMedica has launched an advanced anti-aging medicine program desig

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in

BALTIMORE, June 13, 2025 /PRNewswire/ -- Clear Guide Medical, a leader in AI- and AR-powered surgical guidance technologies, today announced that a peer‑reviewed cadaver study evaluating its LUMENA™ system has been published in the SPIE Digital Library within Proceedings of SPIE Medical Imaging, Volume 13408. The study, titled "Augmented reality system for MRI-guided interventions: a cadaver study", demonstrates the system's potential to enhance MRI-guided needle procedures by improving procedur

RefillGenie helps patients losing Medicaid coverage refill medications without insurance via a fast, affordable telehealth platform. JERSEY CITY, NJ, UNITED STATES, June 13, 2025 / EINPresswire.com / -- RefillGenie , a physician-founded telehealth company specializing in medication refills, is stepping up to bridge critical gaps in healthcare access as millions of Americans risk losing their Medicaid coverage under proposed federal budget cuts. Founded by emergency physician Dr. Stephen Kelly, t

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1

This recall involves removing devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product MedicaLyte Liquid Bicarbonate Concentrate – 45x Proportioning (BC+201) Unique Device Identifier (UDI)/Model: 00817411022824 What to Do On June 2, Nipro sent all affected customers an updated letter recommending the following actions: Do not use any MedicaLyte Liquid Bicarbonat

DUBLIN--(BUSINESS WIRE)--The "High Throughput Process Development - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for High Throughput Process Development was valued at US$15.3 Billion in 2024 and is projected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Th